Matrix effects in metabolite quantification for mist assessment: The impact of phospholipid removal and hplc column particle size

Bioanalysis

Volumn 6, Issue 6, 2014, Pages 761-771

  Danaceau, Jonathan ^a   Yu, Hongbin ^b   Chambers, Erin ^a   Fountain, Kenneth J ^a  

^a WATERS CORPORATION   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANDROSTANOLONE; CLOPIDOGREL; CLOPIDOGREL CARBOXYLIC ACID; CLOZAPINE; DRUG METABOLITE; FENTANYL; FEXOFENADINE; MIDAZOLAM; NORCLOZAPINE; NORFENTANYL; NORTRIPTYLINE; PALIPERIDONE; PHOSPHOLIPID; QUETIAPINE; RADAFAXINE; RISPERIDONE; TERFENADINE; TESTOSTERONE; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MEASUREMENT ACCURACY; PARTICLE SIZE; PRECIPITATION; QUANTITATIVE ANALYSIS; METABOLISM; PROCEDURES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MASS SPECTROMETRY; PHOSPHOLIPIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898743291     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.330     Document Type: Article

References (18)

1. US FDA. Guidance for Industry: Safety Testing of Drug Metabolites. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM079266.pdf
2. ICH. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (2009). www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Multidisciplinary/ M3-R2/Step4/M3-R2-Guideline.pdf
3. Yu H, Bischoff D, Tweedie D. Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance. Expert Opin. Drug Metab. Toxixol. 6(12), 1539-1549 (2010).
4. Baillie TA. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem. Res. Toxicol. 22(2), 263-266 (2009).
5. Ma S, Li Z, Lee KJ, Chowdhury SK. Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds. Chem. Res. Toxicol. 23(12), 1871-1873 (2010).
6. Schadt S, Chen L-Z, Bischoff D. Evaluation of relative LC-MS response of metabolites to parent drug in LC/nanospray ionization mass spectrometry: potential implications in MIST assessment. J. Mass Spectrom. 46(12), 1282-1287 (2011).
7. Gao H, Deng S, Obach RS. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. Drug Metab. Dispos. 38(12), 2147-2156 (2010).
8. Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC-MS/MS analyses. J. Chromatogr. B 852(1-2), 22-34 (2007).
9. Lahaie M, Mess J-N, Furtado M, Garofolo F. Elimination of LC-MS/MS matrix effect due to phospholipids using specific solid-phase extraction elution conditions. Bioanalysis 2(6), 1011-1021 (2010).
10. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC?MS/MS. Anal. Chem. 75(13), 3019-3030 (2003).
11. Neville D, Houghton R, Garrett S. Efficacy of plasma phospholipid removal during sample preparation and subsequent retention under typical UHPLC conditions. Bioanalysis 4(7), 795-807 (2012).
12. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 9(1), E109-E114 (2007).
13. ChemAxon. Chemicalize. www.chemicalize.org
14. Xia Y-Q, Jemal M. Phospholipids in liquid chromatography-mass spectrometry bioanalysis: comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipids elution and the association of phospholipids with matrix effects. Rapid Commun. Mass Spectrom. 23(14), 2125-2138 (2009).
15. Little JL, Wempe MF, Buchanan CM. Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: examining lipid matrix ionization effects in plasma. J. Chromatogr. B 833(2), 219-230 (2006).
16. Matuszewski BK, Chavez CM, Constanzer ML. Development of high-performance liquid chromatography-tandem mass spectrometric methods for the determination of a new oxytocin receptor antagonist (L-368,899) extracted from human plasma and urine: a case of lack of specificity due to the presence of metabolites. J. Chromtogr. B 716, 195-208 (1998).
17. Yan Z, Maher N, Torres R, Caldwell GW, Huebert N. Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19(22), 3322-3330 (2005).
18. Vrbanac JJ, Hilgers A, Dubnicka T, Shilliday FB, Humphries D, Hayes RN. High-resolution isotope-dilution mass spectrometry using metabolism of isotope-labeled compounds: application to drug metabolites. Rapid Commun. Mass Spectrom. 26(22), 2569-2576 (2012).